AVGO ended June with a small recovery — up 1.4% on Tuesday to close at $377.75 — but the gap between where the stock trades and where the Street thinks it belongs remains extraordinarily wide, and a cluster of insider sales this week adds an uncomfortable counterpoint to the bull case.
The insider activity is the most pointed data point of the week. Chairman Henry Samueli sold roughly 253,000 shares across multiple tranches on June 24, raising close to $100 million in aggregate. Chief Legal Officer Mark Brazeal followed on June 25 with a $9.7 million sale at $387. These are not trivial executions. Combined with a 90-day net insider transaction figure showing $260 million in net proceeds, the picture is one of systematic distribution from the top of the house — at prices that sit roughly 30% below where the Street's mean target of $523 places fair value. Insiders and analysts are telling opposite stories.
Short positioning offers no useful tension. Short interest is only 1.3% of the free float — genuinely low — and though it has risen about 10% over the past week and 14% over the past month, the absolute level is inconsequential for a stock of this size. Borrow availability is effectively unconstrained, with close to 3.9 billion shares available to lend. Cost to borrow has ticked up 41% week-on-week, reaching 0.43%, but that move comes off an extremely low base and still signals almost zero structural conviction from the bear side. Options positioning reinforces the same read: the put/call ratio at 1.06 has actually drifted slightly below its 20-day average of 1.10, producing a mildly negative z-score. If anything, hedging demand has eased into month-end, not intensified.
The Street, for its part, has not flinched. All the major analyst actions — from JP Morgan's $580 target to the $530–$550 cluster at Jefferies, Truist, B of A Securities, and Mizuho — were set on June 4, the same session the stock cratered 19.5% on earnings. Not one has been revised since. That cluster of unchanged targets now implies between 25% and 54% upside from Tuesday's close. The bulls point to AI accelerator demand, the OpenAI "Jalapeño" chip partnership, and a VMware software base that adds recurring revenue. The bears flag elevated debt, customer concentration risk around hyperscaler AI budgets, and a stock that has now fallen 15% over the past month despite a record Q2 print and the Google supply deal confirmation. Valuation has compressed meaningfully — the P/E multiple has dropped roughly 4.5 turns over the past 30 days to around 24.9x, and EV/EBITDA has shed 1.6 turns to 19.8x — yet those multiples still sit above the semiconductor sector median, which the EV/EBIT factor score ranking in the 38th percentile reflects.
The peer tape provided some relief on Tuesday. NVDA gained 2.6% on the day, AMD surged 7.7%, and MU added 0.8% — a broad semiconductor bid that lifted AVGO along with it. On the week, though, AVGO's flat-to-down 0.6% move lags AMD's 11.7% gain and MU's 9.7% advance materially, which suggests the stock is underperforming its closest peers as the sector recovers. The earnings history provides the starkest context: the most recent print delivered a 19.5% single-day drop, and a five-day loss of 19.5% that held. The print before that also saw a 13% one-day decline with a 22.7% five-day loss. Both moves came despite strong underlying results. The next earnings date is September 3.
What to watch into Q3 is whether the analyst community begins cutting targets to close the gap with price — or whether AVGO starts climbing back toward $450–$470 before the September print, which would be the first genuine test of whether the post-earnings collapse has found a durable floor.
See the live data behind this article on ORTEX.
Open AVGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
